GlobeNewswire by notified

Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in ONWARDS 5 phase 3a trial

Share

Bagsværd, Denmark, 3October 2022 – Novo Nordisk today announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes.

The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300) in 1,085 insulin-naïve people with type 2 diabetes in a clinical practice setting including fewer trial visits compared to the other ONWARDS phase 3a trials. Once-weekly insulin icodec was used in combination with a dosing guide app to guide titration.

The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 52 with insulin icodec compared with once-daily basal insulin analogues. From an overall baseline HbA1c of 8.9%, once-weekly insulin icodec achieved a superior reduction in estimated HbA1c of –1.68%-points compared with –1.31%-points for the once-daily basal insulins (estimated treatment difference: –0.38%-points).

In the trial, there was no statistically significant difference in estimated rates of severe or clinically significant hypoglycaemia (blood glucose below 3 mmol/L) with 0.19 events per patient-year exposed to once-weekly insulin icodec and 0.14 events per patient-year exposed to the once-daily basal insulins. In the trial, once-weekly insulin icodec appeared to have a safe and well-tolerated profile.

“We are very pleased to share the positive results from the ONWARDS 5 trial. These results include real-world elements and a dosing guide app, which help us better understand how insulin icodec can make a difference for patients in a clinical practice setting,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk. “Today’s results confirm the results from the previous reported ONWARDS trials and highlight that insulin icodec has the potential to be an ideal insulin for people with type 2 diabetes. We now look forward to sharing the results with regulatory authorities.”

Novo Nordisk expects to file for regulatory approval of once-weekly insulin icodec in the US, the EU and China in the first half of 2023.

About the ONWARDS clinical development programme
The ONWARDS programme for once-weekly insulin icodec currently comprises six phase 3a global clinical trials, including a trial with real-world elements, involving more than 4,000 adults with type 1 or type 2 diabetes.

ONWARDS 1 is a 78-week trial comparing the efficacy and safety of once-weekly insulin icodec with once-daily insulin glargine U100 both in combination with non-insulin anti-diabetic treatment in 984 insulin-naïve people with type 2 diabetes. Following the completion of the main phase of the trial, a 26-week extension phase is ongoing. The results of the main phase were reported on 3 June 2022.

ONWARDS 2 was a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin degludec in 526 people with type 2 diabetes switching from a once-daily insulin. Results were reported on 28 April 2022.

ONWARDS 3 was a 26-week trial comparing once-weekly insulin icodec with once-daily insulin degludec. The objective of the trial was to assess the efficacy and safety of insulin icodec in 588 insulin-naïve people with type 2 diabetes. Results were reported on 29 July 2022.

ONWARDS 4 was a 26-week trial comparing once-weekly insulin icodec with once-daily insulin glargine, both in combination with mealtime insulin. The objective of the trial was to assess the efficacy and safety of insulin icodec in 582 people with type 2 diabetes treated with basal and bolus insulin. Results were reported on 29 July 2022.

ONWARDS 5 was a 52-week trial comparing once-weekly insulin icodec with once-daily basal insulin (insulin degludec and insulin glargine U100 and U300) The objective of the trial was to assess the effectiveness and safety of insulin icodec, with an app providing dosing recommendation, in 1,085 insulin-naïve people with type 2 diabetes in a clinical practice setting including no upper limit at HbA1c at time of inclusion, no limitations on use of oral antidiabetic treatments and fewer planned site visits compared to the other ONWARDS phase 3a trials (every third month in accordance with recommended clinical practice)

ONWARDS 6 is a 52-week trial comparing once-weekly insulin icodec with once-daily insulin degludec, both in combination with mealtime insulin. The objective of the trial is to assess the efficacy and safety of insulin icodec in 583 people with type 1 diabetes. Following the completion of the main phase of the trial, a 26-week extension phase is ongoing. The results of the main phase were reported on 3 June 2022.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Twitter, LinkedIn andYouTube.

Further information

Media:
Ambre Brown Morley+45 3079 9289abmo@novonordisk.com
Natalia Salomao Abrahao (US)+1 848 304 1027niaa@novonordisk.com
Investors: 
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com
Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com
Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com

Company announcement No 73 / 2022

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Transactions in connection with share buyback programme5.12.2022 08:26:06 CET | Press release

On 27 April 2022, Tryg A/S (“Tryg”) announced that a share buyback programme of DKK 5.0 billion had been initiated as a result of the sale of Codan Denmark. The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme will end no later than 03 July 2023. Transactions made under the share buyback programme will be announced through Nasdaq Copenhagen on a weekly basis. The following transactions have been executed in the period 28 November 2022 to 02 December 2022: Number of sharesAvg. purchase price, DKKTransaction value, DKK28 November 2022 100,000 163.64 16,364,000 29 November 2022 120,000 164.39 19,726,800 30 November 2022 100,000 165.60 16,560,000 01 December 2022 90,000 168.50 15,165,000 02 December 2022 90,000 169.19 15,227,100 Accumulated for the period500,000-83,042,

AS Tallink Grupp Statistics for November 20225.12.2022 08:00:00 CET | Press release

In November 2022, AS Tallink Grupp transported 378 540 passengers, which is a 7.6% increase compared to November 2021. The number of cargo units decreased by 5.6% to 33 502 units and the number of passenger vehicles increased by 5.1% to 52 688 units in the same comparison. AS Tallink Grupp passenger, cargo unit and passenger vehicles numbers for November 2022 were the following: November 2022November 2021ChangePassengers378 540351 8577.6%Finland – Sweden131 606147 383-10.7%Estonia – Finland207 071172 22820.2%Estonia – Sweden39 86332 24623.6%Cargo Units33 50235 486-5.6%Finland – Sweden4 0666 724-39.5%Estonia – Finland24 99923 4716.5%Estonia – Sweden4 4375 291-16.1%Passenger Vehicles52 68850 1135.1%Finland – Sweden3 8045 463-30.4%Estonia – Finland47 55542 94510.7%Estonia – Sweden1 3291 705-22.1% FINLAND – SWEDEN November results reflect operations of Turku-Kapellskär and Helsinki-Stockholm routes. The cruise ferry Galaxy stopped operating on the Turku-Stockholm route in September 2022 du

Norsk Hydro: Status tilbakekjøp av egne aksjer5.12.2022 08:00:00 CET | Pressemelding

Nedenfor er informasjon om transaksjoner foretatt under tilbakekjøpsprogrammet for Norsk Hydro ASA. Dato for når tilbakekjøpsprogrammet ble annonsert: 23. september 2022 Tilbakekjøpsprogrammets varighet: 29. mars 2023 Oversikt over transaksjoner: Dato Aggregert daglig volum (antall aksjer)Gjennomsnittpris (NOK)Total transaksjonsverdi (NOK)28.11.2022140 00071,8710 062 47229.11.2022138 00072,8810 057 38530.11.2022135 00073,049 860 09001.12.2022135 00073,039 859 37402.12.2022135 00072,489 784 611Tidligere transaksjoner 6 895 000Totalt offentliggjorte tilbakekjøp under programmet7 578 00065,24494 405 379 I forkant av tilbakekjøpsprogrammet eide Norsk Hydro totalt 16 452 403 egne aksjer. Etter gjennomføringen av overnevnte transaksjoner, eier Norsk Hydro ASA totalt 24 030 403 egne aksjer, tilsvarende 1,16% av Norsk Hydro ASAs aksjekapital. Vedlegg: En oversikt over alle gjennomførte handler under tilbakekjøpsprogrammet som er uført i overnevnte tidsperiode er vedlagt denne meldingen og tilg

Equinor ASA: Share buy-back5.12.2022 08:00:00 CET | Press release

Please see below information about transactions made under the share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR). Date on which the fourth tranche of the share buy-back programme for 2022 was announced: 28 October 2022. The duration of the fourth tranche of the buy-back programme for 2022: 31 October to no later than 27 January 2023. Size of the buy-back programme: Up to 75,000,000 shares, with a maximum total consideration for the fourth tranche: USD 604,890,000. From 28 November until 2 December, Equinor ASA has purchased a total of 1,587,853 own shares at the Oslo Stock Exchange at an average price of NOK 370.4728 per share. Aggregated overview of transactions per day: DateAggregated volume (number of shares)Weighted average share price (NOK)Total transaction value (NOK)28 November330,000358.4478118,287,774.0029 November319,628371.4527118,726,683.6030 November311,000379.0950117,898,545.001 December310,000377.5002117,025,062.002 December317,225366.6746116,318,349.99Previ

Norsk Hydro: Status share buyback program5.12.2022 08:00:00 CET | Press release

Please see below information about transactions made under the share buy-back program for Norsk Hydro ASA. Announcement date of the share buyback program: September 23, 2022 End date of the share buyback program: March 29, 2023 Overview of transactions: Date Aggregate daily volume (no. of shares) Average price (NOK) Total transaction value (NOK) 28.11.2022140 00071.8710 062 47229.11.2022138 00072.8810 057 38530.11.2022135 00073.049 860 09001.12.2022135 00073.039 859 37402.12.2022135 00072.489 784 611Previous transactions 6 895 000Total transaction under the program7 578 00065.24494 405 379 Prior to the share buyback program Norsk Hydro ASA owned a total of 16 452 403 own shares. Following the above listed transactions, Norsk Hydro ASA owns a total of 24 030 403 shares, corresponding to 1.16% of Norsk Hydro ASA's share capital. Attachment: An overview of all the completed transactions under the program for the dates specified above is attached to this notification and available on www.n